A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

Disease (cancer type)

Lung Cancer

Contact information

  • North Florida / Jacksonville: Rhonda Calhoun (904) 427-1217

Patient Selection Criteria

Documented (radiographic evidence of) relapse or disease progression during or after first-line platinum-based therapy (subjects refractory to initial platinum-based therapy are eligible).

Research sponsor

United Therapeutics

State(s)

  • Florida

Linked Physicians

Back
To top